CA
NBIX icon

CastleArk Alternatives’s Neurocrine Biosciences NBIX Stock Holding History

CastleArk Alternatives’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,405
Closed -$135K – 188
2021
Q3 		$135K Buy
+1,405
New +$133K 0.01% 307

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
EVM
Eaton Vance Management Boston, Massachusetts $67.5B AUM 11.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CastleArk Alternatives's NBIX Position: Q4 2021 in Review

CastleArk Alternatives sold out of Neurocrine Biosciences (NBIX) in Q4 2021, closing a stake of 1,405 shares — an estimated $135K sold.

CastleArk Alternatives first reported a position in NBIX in Q3 2021 and held it in 1 quarter. The position peaked at $135K in Q3 2021. 405 funds tracked by Wall St. Rank hold NBIX as of Q4 2021.

  • CastleArk Alternatives reported no remaining Neurocrine Biosciences position as of Q4 2021 after selling out during the quarter.
  • CastleArk Alternatives sold 1,405 Neurocrine Biosciences shares in Q4 2021, an estimated $135K.
  • CastleArk Alternatives first reported a position in Neurocrine Biosciences in Q3 2021 and held it in 1 quarter.
  • CastleArk Alternatives's Neurocrine Biosciences position peaked at $135K in Q3 2021.
  • 405 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.